Hexanucleotide repeat expansions in the C9orf72 gene are the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). How this mutation leads to these neurodegenerative diseases remains unclear. Here, we use human induced pluripotent stem cell-derived motor neurons to show that C9orf72 repeat expansions impair microtubule-based transport of mitochondria, a process critical for maintenance of neuronal function. Cargo transport defects are recapitulated by treating healthy neurons with the arginine-rich dipeptide repeat proteins (DPRs) that are produced by the hexanucleotide repeat expansions. Single-molecule imaging shows that these DPRs perturb motility of purified kinesin-1 and cytoplasmic dynein-1 motors along microtubules in vitro. Additional in vitro and in vivo data indicate that the DPRs impair transport by interacting with both microtubules and the motor complexes. We also show that kinesin-1 is enriched in DPR inclusions in patient brains and that increasing the level of this motor strongly suppresses the toxic effects of arginine-rich DPR expression in a Drosophila model. Collectively, our study implicates an inhibitory interaction of arginine-rich DPRs with the axonal transport machinery in C9orf72-associated ALS/FTD and thereby points to novel potential therapeutic strategies.
derived motor neurons. Consistent with previous observations (19, 26) , these peptides were taken up by the motor neurons ( Fig. S7A-C) . We observed an inhibition of mitochondrial transport in motor neurons treated with arginine-rich DPRs at concentrations that did not trigger cell death (Fig. S7D, Fig. 2A, C-D and Fig S8D-I) . A peptide with 30 PR repeats (PR30) produced a proportionately stronger impairment of mitochondrial transport ( Fig. 2G and Fig. S9A-D) , revealing a repeat-length-dependent effect. Delivery into cells of poly-GP (GP20), which has been shown to be non-toxic (21, 35, 36) , did not affect motility of these organelles ( Fig. 2A-B and Fig. S8A-C) . Besides mitochondria, other cargoes key to neuronal function are also trafficked along axons. These include RNA granules, which contain several proteins encoded by known ALS/FTD-associated genes (51, 52) . We observed that transport of such granules (which can be marked with the SYTO-RNASelect dye ((51)) was reduced upon treatment with a non-lethal concentration of PR20 ( Fig. 2E-F and Fig. S8L-N) . We conclude that arginine-rich DPRs are sufficient to impair transport of cargos in human motor neurons.
Microtubule-based transport is perturbed by arginine-rich DPRs in a reconstituted in vitro system
From the experiments described above, we cannot conclude that arginine-rich DPRs inhibit the microtubule-based transport machinery directly. An alternative possibility is that perturbed axonal transport is a downstream consequence of other cellular processes being impaired. To test if these peptides can directly inhibit transport we used in vitro motility assays with purified motor complexes. Kinesin-1 and dynein were chosen for these experiments as they are the major motors for mitochondrial transport in axons (53) (54) (55) , where they drive anterograde and retrograde movements, respectively. These motors also are also important for the transport of RNA granules in neuronal processes (56) (57) (58) . To evaluate kinesin-1 motility we used a well characterized, constitutively active form of the major human isoform KIF5B tagged with GFP (59) . Dynein motility assays were performed with the fluorescently-labelled human recombinant motor complex in the presence of the essential activators dynactin and BicD2N (60, 61) . Experiments were performed with stabilised microtubules immobilised on a glass surface using concentrations of motor complexes low enough for visualisation of single transport events by total internal reflection fluorescence (TIRF) microscopy.
We first assessed the effects of 20-repeat DPRs on motility of kinesin-1 by introducing them into the motility assay together with the motor complex (Fig. 3A) . GR20 and PR20 significantly reduced the percentage of microtubule-associated kinesin-1 complexes that exhibited processive transport compared to the control in which no peptides were added (Fig. 3B) .
These DPRs also caused a significant decrease in the mean velocity of processive kinesin-1 movements, as well as an increase in the incidence of pausing events within or at the end of a run (Fig. 3B) . GR20 and PR20 had the same consequences on the motility of dynein in the presence of dynactin and BicD2N, although the magnitude of these effects relative to the nopeptide control tended to be smaller than observed for kinesin-1 (Fig. 3C) . In contrast, GP20 did not reduce the percentage of processive events or velocity of either motor, nor increase their incidence of pausing ( Fig. 3A-C) .
Given the strong inhibition of mitochondrial transport in motor neurons by 30 repeats of PR ( Fig. 2G) , we also tested the effect of this peptide on both kinesin-1 and dynein complexes in vitro. Compared to controls lacking peptide, PR30 impaired processive movements of both kinesin-1 and dynein complexes in a dose-dependent manner ( Fig. 3D and Fig. S10A-B) .
The effect of PR30 on dynein was proportionally stronger than observed for PR20 ( Fig. 3E and   Fig. S10C ). In contrast, PR30 and PR20 impaired kinesin-1 motility to a similar extent ( Fig. 3E and Fig. S10D) . Upon further analysis, we found additional differences in the effect of arginine-rich DPRs on kinesin-1 and dynein. First, there were more overall binding events of kinesin-1 on microtubules in the presence of GR20, PR20 and PR30 compared to no peptide controls ( Fig. S11A and Fig. S10D) , whereas there were fewer such events for dynein ( Fig.   S11B and Fig. S10C) . Second, whilst the arginine-rich DPRs prolonged the duration of processive movements for kinesin-1 complexes, the opposite was true for processive dynein complexes (Fig. S11) .
These experiments demonstrate that arginine-rich DPRs perturb motility of both dynein and kinesin-1 in the absence of other potentially confounding cellular processes, although the effect of the peptides on the interactions of the motors with microtubules are not equivalent.
Arginine-rich DPRs bind microtubules in vitro and can impede motor movement
To shed light on how arginine-rich DPRs impair motor movement we monitored their localization in our in vitro motility assay. There was a clear interaction between fluorescentlylabeled GR20, PR20 and PR30 and microtubules, with all three peptides binding along the length of the lattice as well as concentrating in puncta (Fig. 4A) . The strongest overall binding was exhibited by PR30 ( Fig. 4B) , which also exhibited more frequent and more intense puncta than the 20-repeat DPRs (Fig. 4A) . No microtubule association was observed for GP20 ( Fig. 4A, B) . Thus, only those DPRs that perturb motility of kinesin-1 and dynein are able to associate with microtubules.
These observations raised the possibility that microtubule-bound DPRs inhibit transport by impeding the movement of kinesin-1 and dynein along the track. Reducing the concentration of PR30 led to clearly resolvable puncta on microtubules ( Fig. S12 ) that allowed us to investigate discrete interactions of DPRs and motor complexes on microtubules. We quantified the co-incidence of sites of pausing or microtubule detachment of kinesin-1 and dynein with the patches of intense PR30 accumulation and compared the results to control datasets generated with randomized patterns of PR30 foci at an equivalent density ( Fig. 4C-F ). Pause sites and detachment sites for both motors co-incided with a patch of PR30 significantly more often than expected by random chance (Fig. 4D, F) . This result reveals that large accumulations of arginine-rich DPRs can act as obstacles to kinesin-1 and dynein complexes. Our observation that motor velocity along the microtubule was persistently reduced by poly-GR and poly-PR ( Fig. 3A) suggests that the general accumulation of these DPRs along the lattice also affects motor motility.
We also detected instances of each type of motor complex transporting large foci of PR30 along microtubules ( Fig. 4G ; observed for 1.8% of processive kinesin-1 complexes (3/169) and 8.1% of processive dynein complexes (9/111)). Thus, in addition to interacting with microtubules, PR30 can associate with kinesin-1 and dynein-dynactin-BicD2N complexes in our reconstituted system. This observation led us to investigate whether arginine-rich DPRs can interact with microtubules and motors in the complex cellular milieu.
Arginine-rich DPRs interact with microtubule and motor proteins in motor neuron extracts and in vivo
We first asked if PR30 interacts with tubulin and microtubule motors in mouse spinal cord lysate. Incubating the soluble fraction of the lysate with PR30 peptide, but not GP30, lead to the formation of large biomolecular condensates that could be pelleted by gentle centrifugation and analyzed by mass spectrometry (35) (Fig. 5A, B) . The spinal cord interactome of PR30 was strongly enriched for similar gene ontology categories (e.g., RNA granule, translation, proteasome, protein folding) as observed in our previous interactome study using cancer cell extracts (35) (Fig. 5C, Fig. S13A-B , Table S5 ). We also identified a strong enrichment of terms related to intracellular transport ( Fig. 5C-D) . Proteins in this category included those involved in nucleocytoplasmic transport (Table S5) , a process we and others previously implicated in C9orf72 ALS/FTD (19, 21, 22, 25, 34) , and microtubulebased transport (Fig. 5C) . Consistent with the interactions of arginine-DPRs observed in our in vitro motility assays, several isotypes of the α-and β-tubulin subunits of microtubules were precipitated with PR30 ( Fig. 5D, Table S5 ), as were the three different kinesin-1 isoforms Table S5 ). We also detected other classes of kinesins and components of intraflagellar transport dynein (cytoplasmic dynein-2) in the precipitate (Fig. 5D , Table S5 ). These data reveal that PR30 can associate in spinal cord lysate with multiple proteins involved in microtubule-based transport (Fig. 5D , Table S5 ). Several of these factors are mutated in ALS or other neuromuscular disorders ( Fig. 5D , Table S5 ).
The association of arginine-rich DPRs with kinesin-1, dynein and microtubules was further supported by treating control iPSC-derived sMNs with HA-labelled PR20, GR20 and GP20 peptides and subjecting their lysates to immunoprecipitation using anti-HA beads. Robust signals for KIF5B, tubulin and dynein were observed in immunoblots of the material precipitated with PR20 and GR20, but not the material precipitated with GP20 ( Fig. 5E, Fig. 
SC-E).
We next investigated interactions of DPRs with microtubules and motors within intact sMNs using fluorescence microscopy. The broad distribution of microtubules, KIF5B and dynein within cell bodies and along neuronal processes prevented meaningful analysis of interactions with exogenous DPRs at these sites by conventional co-localization analysis.
However, co-localization of signals from poly-PR and tubulin could be detected in growth cones of developing sMNs, in which microtubules are spaced apart ( Fig. S14A) .
Furthermore, duolink proximity ligation assays (62, 63) supported the interaction between PR20 and KIF5B in both the cell body and processes of sMNs ( Fig. S14B) . We also investigated the association of KIF5B with poly-GR in brain sections from two patients with C9orf72 ALS/FTD. Approximately 40% of the cytoplasmic poly-GR inclusions in the sections had enrichment of KIF5B, supporting the association of endogenously expressed argininerich DPRs with this motor ( Fig. 5F-G) . Collectively, these observations strengthen the evidence for physical association of arginine-rich DPRs with the axonal transport machinery.
Altering levels of kinesin-1 strongly modifies defects caused by expression of arginine-rich DPRs in Drosophila
The experiments described above provide evidence that arginine-rich DPRs impair transport directly by interacting with microtubules and motors. However, these data do not indicate whether this activity contributes to the pathomechanism of arginine-rich DPRs in vivo. To address this question, we manipulated the microtubule-based transport machinery in previously described Drosophila models for toxicity of these peptides (20) . We took advantage of a transgene containing the entire Kinesin-1 heavy chain (Khc) locus (P[Khc + ]) that causes an approximately two-fold increase in levels of the Khc protein and significantly increases the frequency of axonal transport of mitochondria in neurons of aged adult flies (64, 65) . Both anterograde and retrograde movements of these organelles is stimulated in these animals, consistent with tight coupling of dynein and kinesin-1 motor activities in many cell types (66) (67) (68) .
We first used flies overexpressing 36 repeats of GR under control of the GMR-GAL4 driver. It has previously been reported that expressing GR36 in this manner results in a high incidence of lethality before adulthood (20) . We also observed substantial lethality in this condition, with ~40% of the expected number of adult flies recovered ( Fig. 6A) . Remarkably, P[Khc + ] almost completely suppressed the lethality caused by GR36 expression (Fig. 6A) . Consistent with this result, inactivating one copy of the endogenous gene encoding Khc significantly enhanced the lethal phenotype compared to flies with wild-type levels of Khc ( Fig. 6A) .
Expression of arginine-rich DPRs also results in a range of abnormalities in the adult eye, including disruption to the external lattice, pigment loss and necrosis (20, 25) . P[Khc + ] also suppressed eye abnormalities caused by GR36 expression compared to a control with wildtype levels of the motor (Fig. S15A) . The strong lethality of GR36-expressing Khc heterozygous mutants meant there were not enough animals for meaningful analysis of eye phenotypes. To more comprehensively investigate the link between motor levels and DPRinduced eye defects, we used a PR36-expressing fly stock that causes eye abnormalities without compromising development to adulthood (20) . Consistent with the genetic interactions with GR36, the severity of eye defects caused by PR36 was suppressed by P[Khc+] and enhanced by reducing Khc gene dosage ( Fig. 6B and Fig. S15B-C) . In control experiments, we determined that in the absence of GR36 or PR36 the changes in Khc gene dosage had no effect on survival or eye morphology (Table S6) .
Collectively, these data reveal that increasing the amount of the kinesin-1 motor suppresses the defects caused by overexpression of poly-GR and poly-PR, which further supports a functional link between the microtubule-based transport machinery and the pathomechanism of arginine-rich DPRs.
DISCUSSION
Axonal transport of organelles and macromolecules by microtubule motors is crucial for neuronal homeostasis and survival. This process facilitates communication between synaptic terminals and the cell body and allows local demands for the functions of organelles and macromolecules to be met (69) . Deficits in microtubule-based transport in axons are linked with several age-related neurodegenerative diseases including Alzheimer's, Huntington's disease and hereditary spastic paraplegia (42) , as well as with ALS caused by mutations in SOD1, TARDBP and FUS (44) (45) (46) (47) 51, 69) . However, whether impaired axonal transport is a cause or consequence of neuronal dysfunction in these contexts remains controversial. The notion that defective intracellular trafficking can directly trigger ALS has been strengthened by the discovery of disease-causing mutations in several genes encoding components of the microtubule-based transport machinery, namely TUBA4A, DCTN1 and KIF5A (39) (40) (41) .
These mutations have been reported to disturb the dynamics of microtubules or the trafficking of cargos along them (39, 40, (70) (71) (72) (73) (74) .
Despite evidence of defective axonal transport in other forms of ALS, the literature on C9-ALS/FTD has focused on other potential disease mechanisms (75) . Here, we report that the disease-causing HREs in the C9orf72 gene impair transport in neurites of human iPSCsderived sMNs. These data indicate that deficits in intracellular trafficking of cargoes are a common feature of ALS pathogenesis.
Although both loss-and gain-of-function disease mechanisms have been proposed in C9-ALS/FTD (75) , the transport impairment in the patient-derived motor neurons was not associated with a reduction in overall C9orf72 mRNA levels. However, we found that administration of the arginine-rich DPRs that are produced from C9orf72 HREs inhibits transport of mitochondria and RNA granules in sMNs derived from healthy individuals. These observations, which are in line with the ability of PR36 to increase the stationary fraction of mitochondria in a Drosophila model (45) , suggest a primarily gain-of-function mechanism in human neurons involving inhibition of axonal transport by poly-PR and poly-GR. The relevance of perturbed microtubule-based transport to the pathomechanism of arginine-rich DPRs is supported by our finding that changes in kinesin-1 gene dosage strongly modify the toxic effects of arginine-rich DPRs in Drosophila. Most strikingly, we found that boosting levels of kinesin-1, which we previously showed increases the frequency of anterograde and retrograde axonal transport in adult flies (65) , almost completely suppresses the lethality caused by GR36 expression.
Our in vitro motility assays reveal that poly-GR and poly-PR can directly perturb microtubulebased transport of kinesin-1 and dynein, which are key motors in the trafficking of many cargoes in neurons, including mitochondria (53) (54) (55) and RNA granules (56) (57) (58) . These peptides have a range of effects on motor behavior, including reducing the fraction of microtubule-associated complexes that are processive, as well as slowing the movement of processive complexes and increasing their incidence of pausing. We show that arginine-rich DPRs can associate with microtubules in vitro suggesting that they directly interfere with motor translocation along the track. Consistent with this notion, large puncta of microtubuleassociated PR30 can act as obstacles for kinesin-1 and dynein, stimulating motor pausing or detachment. This effect is reminiscent of the ability of the MAPT (tau) protein to partition into patches on microtubules and obstruct the motility of kinesin-1 and dynein complexes in vitro (76) (77) (78) (79) (80) . Mutations in both MAPT and C9orf72 have been shown to cause FTD (81) and it was recently proposed that this reflects a shared inhibitory effect on nucleocytoplasmic transport (82) . The ability of both arginine-rich DPRs and MAPT to impede the motors responsible for transport in the cytoplasm offers another possible explanation for the overlapping features of C9-ALS/FTD and MAPT-FTD.
We also detect physical association of arginine-rich DPRs with kinesin-1 and components of the dynein-dynactin transport complex, which could also contribute to the inhibition of transport. Indeed, the reduced velocity and increased pausing of both types of motor in the presence of arginine-rich DPRs in vitro is compatible with their retardation by transient interactions with microtubule-associated peptides.
Intriguingly, not all properties of kinesin-1 and dynein are affected equivalently by argininerich DPRs. While the peptides increase the frequency of kinesin-1 binding to microtubules and the duration of its processive runs, the opposite is true for dynein. These observations indicate that the overall interactions of kinesin-1 and dynein complexes with microtubules are increased and decreased, respectively, by arginine-rich DPRs. Whilst the mechanistic basis of this differential effect warrants further investigation, our current results highlight how either strengthening or weakening interactions with microtubules can prevent efficient translocation of motors along the track.
We found that transport of both mitochondria and RNA granules in sMNs is perturbed by arginine-rich DPRs. Given the widespread roles of kinesin-1 and dynein in intracellular transport (83, 84) , as well as our discovery of other classes of microtubule motors in the PR30 interactome from sMNs, it is likely that the trafficking of several cargoes is disrupted by these peptides. Whether altered translocation of a specific cargo type is of particular significance for C9-ALS/FTD remains to be resolved. However, the observation that ALS/FTD-associated mutations in the RNA-binding protein TDP-43 alter its bidirectional transport along microtubules in axons (51) suggests that RNA trafficking abnormalities contribute to disease pathology. Consistent with this hypothesis, TDP-43 has been detected, like KIF5B in this study, in endogenous GR inclusions in C9-ALS/FTD post-mortem tissue (85) .
Whilst our results support a direct inhibitory effect of arginine-rich DPRs on axonal transport, we cannot rule out that other processes also contribute to the trafficking defects we observe in C9-ALS/FTD neurons. In addition to defective nucleocytoplasmic transport, altered RNA splicing, translation, and membrane-less organelle dynamics, as well as elevated mitochondrial and ER stress have been linked to the disease (14, 21, 22, 25, 26, (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) . It is possible that one or more of these processes exacerbates the transport defects associated with binding of arginine-rich DPRs to the axonal transport machinery. Nonetheless, our data indicate that manipulating microtubule-based transport could be an effective strategy to hinder the progression of C9-ALS/FTD, possibly in conjunction with therapies that target other processes affected by the HREs.
MATERIAL AND METHODS

Cell culture and motor neuron differentiation
C9orf72 iPSC lines were generated from dermal fibroblasts from ALS (C9-2B and C9-3B) and ALS/FTD (C9-1B and C9-4B) patients carrying the G4C2 repeat expansion in the C9orf72 gene ( Table S1 ). Controls were generated from unrelated healthy individuals. Con 1B and Con 2B were purchased from Takara Bio Inc (ChiPSC-6b, P11031) and Sigma (iPSC Epithelial-1, IPSC0028), respectively. Con 3B, C9-1B, C9-2B, C9-3B and C9-4B were generated using the CytoTune™-iPS 2.0 Sendai Reprogramming Kit (ThermoFisher Scientific, A16517). qRT-PCR for Sendai virus clearance was performed and did not detect residual Sendai virus RNA in any of the tested iPSC lines. iPSCs were kept in in Essential 8™ flex medium (A28583-01, Gibco TM ) with 1000 U/ml penicillin-streptomycin. Colonies were passaged every week with 0.5 mM EDTA (15575-020, Invitrogen) diluted in Dulbecco's phosphate-buffered saline (DPBS) and plated on GeltrexR LDEV-Free, hESC-Qualified, Reduced Growth Factor Basement Membrane Matrix (A1413302, Gibco TM ). The absence of mycoplasma contamination was routinely confirmed by PCR. Controls (Con-1B, Con-2B and Con-3B) and C9orf72 (C9-1B, C9-2B, C9-3B and C9-4B) iPSCs were differentiated into spinal motor neurons as previously described (44, 86) . The controls (Con-1 and Con-2), the isogenic controls (C9-1∆, C9-2∆, C9-3∆) and the C9orf72 counterparts (C9-1, C9-2 and C9-3) were obtained and differentiated as reported in Selvaraj et al., 2018 (48) .
Immunocytochemistry
Coverslips were incubated for 20 min at room temperature in phosphate-buffered saline (PBS) with 4% paraformaldehyde and washed three times with PBS. Cells were incubated for 1 h at room temperature in PBS containing 0.1% Triton X-100 (Acros Organics) and 5% donkey (Sigma) or goat (Dako) serum. Cells were incubated with primary antibodies diluted in PBS containing 0.1% Triton X-100 and 2% serum overnight at 4 °C. Cells were rinsed three times in PBS before the secondary antibody was added for 1 h at room temperature.
See Table S7 for details of primary and secondary antibodies. After washing with PBS, the coverslips were incubated for 20 min in PBS/DAPI (NucBlue™ Live ReadyProbes™ Reagent, Invitrogen, R37605). Coverslips were rinsed three times with PBS before mounting in ProLong™ Gold antifade reagent (Invitrogen, P36934). Confocal images were obtained using a Leica SP8 DMI8 confocal microscope. Images were analyzed, formatted and quantified with ImageJ software.
Pluripotency characterization
iPSCs cells were subjected to spontaneous differentiation mediated by the formation of embryoid bodies (EBs), and subsequently analyzed for the three-lineage differentiation using the ScoreCard methodology (87) (ThermoFisher Scientific). On the day of EB formation, 60-80% confluent iPSCs were washed with PBS and incubated with 0.5 mM EDTA (15575-020, Invitrogen) for 1-3 min to dissociate the colonies. Cells were harvested in Essential 8™ flex medium (A28583-01, Gibco TM ) and counted before gently spinning down at 300 x g for 5 min.
Cells were plated in a 24 well Corning® Ultra-Low Attachment Surface plates (Corning, 3473) at the density of 1.5 × 10 6 cells/well. The plates were incubated overnight at 37°C. The following day, half of the Essential 8™ flex medium was replaced with Essential 6™ medium (A15164-01, Gibco TM ). For the spontaneous differentiation, the EBs were kept for 14 days in the E6 medium, which was changed every 2 days. After 14 days in culture, EBs were collected for RNA extraction with the GenElute Mammalian Total RNA kit (Sigma, RTN350).
cDNA synthesis was performed with Superscript TM III (ThermoFisher Scientific, 11752-050) and qPCR was performed according to the manufacturer's protocol with TaqMan hPSC Scorecard assay (ThermoFisher Scientific, A15871). Data were analyzed with the online Scorecard software (ThermoFisher Scientific).
Real-time PCR
Total RNA extraction was performed with the GenElute Mammalian Total RNA kit (Sigma). 
Southern blotting
Southern blots were performed as described previously (88) 
Enzyme-linked immunosorbent assay (ELISA)
Poly-GP and poly-GA levels in control and C9orf72 derived sMNs lysates were measured 
Cell viability assay
Cell viability after DPR treatment was measured using DRAQ7™ (Abcam, ab109202) far-red fluorescent DNA dye. DRAQ7 is a cell impermeable dye that only stains the nuclei in cells with a compromised cell membrane, i.e. that are in the process of dying. DRAQ7 was added to each well at a concentration of 3 µM together with Hoechst 33342 (1:1000 Thermo Fisher Scientific, H1399) and incubated for 20 min at 37 °C. Cells were then washed once with DMEMF12 and fixed with 4% paraformaldehyde in PBS for 20 min. For this experiment, motor neurons were cultured in a CellCarrier 96-well plate (Perkin Elmer, UK). Motor neurons were treated with the respective synthetic peptides (PR20, GR20, GP20; Pepscan) and the analysis was performed 24 h after treatment. Untreated cells were used as the control group for PR20 and GR20. To allow the uncharged peptide, GP20, to pass the cellular membrane, based on a previously described analysis algorithm (90) . Neurites with at least one moving organelle were considered for the analysis. Spatio-temporal maps, or kymographs, were generated for each neuronal process in order to distinguish stationary mitochondria and moving mitochondria. The numbers of stationary and moving mitochondria were calculated by counting straight and diagonal lines on the kymographs.
In order to determine the directionality of the transport, cells were sparsely transduced with lentivirus expressing mitoDsRed2 at day 16 of the sMNs differentiation using an MOI of 0.5, 
Proteins and dipeptide repeats
Full length human dynein with a SNAPf-tag on Dynein heavy chain was expressed in Spodoptera frugiperda Sf9 cells and purified and labelled with fluorophores as described previously (61, 92) . SNAPf::BICD2N (not labelled with a fluorophore) was also produced from Sf9 cells using published methods (61) . Native dynactin was purified from pig brain by SPsepharose-based purification as described (93) . (4000 x g spin) and washed in buffer A. Further purification was achieved through a microtubule pull down and release procedure, which enriches for the intact, active motor domain over degradation products (94) . The protein sample was incubated with taxolstabilised microtubules (15 mg mL -1 ) and 1 mM AMP-PNP (Sigma) and the mixture overlaid on a glycerol cushion (BRB80: 80 mM PIPES, pH 6.9, 1 mM EGTA, 1 mM MgCl2), 20 μM taxol and 60% glycerol (v/v)). Centrifugation was performed with a TLA 100 rotor at 317,000
x g for 10 min. The pellet was resuspended in BRB80 with 50 mM KCl and 5 mM ATP and incubated for 10 min to trigger release of microtubule-bound motors. Centrifugation at 317,000 x g for 10 min yielded supernatant containing the released active motors, which were snap frozen in small aliquots in 20% glycerol (v/v) and stored at -80 ˚C.
Porcine tubulin conjugated to fluorophores or biotin was purchased from Cytoskeleton, Inc.
HPLC-purified dipeptide repeats were purchased from Pepscan and were either labelled with a single Cy5 dye at the N-terminus during synthesis or were labelled non-site-specifically inhouse using Alexa488-Fluor® Protein Labeling Kit (Thermo Fisher Scientific) using published methods (95) .
Single molecule motility assays
Biotinylated and fluorescently-labelled porcine microtubules stabilised with taxol and GMP-CPP, PEG-biotin passivated glass surfaces, and motility chambers were prepared as described previously (92, 96) . 
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An independent assembly of dynein, dynactin and BICD2N was used for each dynein assay chamber. Kinesin-1::GFP solutions were diluted 1 in 20 into kinesin-1 motility buffer in the presence or absence of DPRs at the final concentrations indicated in the Results section.
Dynein, dynactin, BICD2N assembly mixtures were diluted 133-fold (with the exception of the complexes in Fig. 3C and Fig. S11B . 3D and Fig. S10A , where one chamber was imaged.
Kymographs were generated and manually analysed using Fiji (99) . . 3D-E and Fig. S10 .
Blinding was not possible in these cases because either the magnitude of the effects on motility made it clear from which conditions the kymographs were derived or the batch of kymographs for analysis contained a single condition.
Interactions of fluorescently labelled motors with microtubules were operationally considered as binding events if they were ≥ 2 s (4 frames) in duration. As described previously (61) , 
Quantification of in vitro microtubule binding by peptides
To quantify microtubule binding by Cy5-labelled DPRs, five TRITC-labelled microtubules were selected randomly from three images acquired from three independent chamber preparations. Mean Cy5 fluorescent intensity was then calculated using Fiji. Background signal was first subtracted with a rolling ball radius of 50 pixels to generate uniform fluorescent intensity across the region. Enrichment of fluorescence on microtubules was calculated by subtracting mean 'background intensity' from microtubule-associated intensity.
Background intensity was calculated from five lines per image equivalent to the median length of microtubules assessed, which were positioned in microtubule-free areas close to the selected microtubules. Binding in Fig. 4A-B was quantified in the presence of the kinesin-1 complex and kinesin motility buffer; however, we verified in separate analyses that the presence of motors is not required for MT binding.
Analysis of motor pausing and detachment on PR30-decorated microtubules
Single-molecule motility data for each motor was acquired as described above. Additional analysis of the co-localization of pause and detachment sites for kinesin-1 and dynein with intense PR30 puncta was carried out in Fiji. Co-incidence was scored if there was at least a 2pixel overlap between the PR30 signal and signal from the incoming motor complex. For the simulated control, randomized patterns of PR30 foci were generated by overlaying the PR30 binding pattern from other microtubules within the same field of view onto the kymographs of motor events on the original microtubule. This procedure led to simulated PR30 banding patterns of equivalent density. Original and simulated images were assessed blind to their identities to avoid unconscious bias.
Mouse husbandry and procedures
All mouse husbandry and procedures were performed in accordance with institutional guidelines and approved by the Stanford Administrative Panel on Animal Care (APLAC).
C57BL/6 mice (Jackson Laboratory) were used. For spinal cord dissection, mice were anesthetized with isoflurane and transcardially perfused with 0.9% saline. Isolated spinal cords were used immediately for sample preparation.
PR30 protein precipitation
Mouse spinal cords were disintegrated in PBS buffer with Halt Protease inhibitor (Thermo For crosslinked samples (see Table S5 ), after incubation with PR30, paraformaldehyde (Sigma-Aldrich) was added to a final concentration of 0.5% for 5 min. 500 μl of 2 M Glycine (Sigma-Aldrich) was added for 5 min to quench paraformaldehyde. Samples were subsequently treated as uncrosslinked samples. Samples for analysis by SDS-PAGE and silver staining were generated identically. Silver staining (Thermo Fisher Scientific) was performed according to the manufacturer's instructions. Proteins were quantified by the MaxLFQ algorithm integrated in the MaxQuant software (101) . A minimum ratio count of two unique or razor peptides was required for quantification.
Proteomics sample preparation and LC-MS/MS analysis
Further data analysis was performed with the Perseus software (version 1.5.3.0) after loading the protein groups file from MaxQuant. Proteins only identified by site and reverse database hits were removed. Missing values were imputed from a normal distribution around the detection limit.
Co-Immunoprecipitation
Motor neurons were treated with 10 µM of HA-labelled DPR peptides (PR20, GR20, GP20;
Pepscan) for 3 h. Subsequently, medium was removed and washed once with ice-cold DPBS (Sigma). Motor neurons were gently scraped off the dish and centrifuged for 5 min, 400 x g at 4 °C. Cell pellets were crosslinked using 1% PFA (Sigma) in DPBS (Sigma) and incubated for 10 min at room temperature. The crosslinking reaction was stopped with 1/10 volume of 1.25 M glycine pH 8 (Thermo Fisher Scientific). Crosslinked cell pellets were washed 3 times with ice-cold DPBS followed by lysis or snap freezing and storage at -80°C. Cell pellets were lysed in ice-cold lysis buffer (150 mM NaCl, 25 mM Tris, 1 mM EDTA, 1% NP40, 5% glycerol, pH 7.4) supplemented with complete EDTA-free protease inhibitor cocktail (Roche Diagnostics). Cell debris was removed via centrifugation and supernatants mixed with Pierce Anti-HA magnetic beads (Thermo Fisher Scientific). The mixture was incubated for 1 h at room temperature with agitation. Afterwards, the beads were washed 3 times with lysis buffer.
The HA-tagged dipeptides and associated material were eluted using the manufacturer's buffers.
For western blot analysis, samples were resolved on 4-20% mini-protean TGX stain-free gels (Biorad) and transferred to nitrocellulose membrane (Biorad). Membrane was blocked with 5% non-fat milk (Biorad) in Tris Buffer Saline Solution with 0.1% tween (TBST) for 2 h at room temperature and incubated with primary antibodies overnight at 4 °C (Table S7 ). The next day the membranes were washed 3 times with TBST and incubated for 1 h with secondary Trueblot antibodies (Rockland). Proteins were detected by enhanced chemiluminescence reagents (Thermo Fisher Scientific).
Proximity ligation assay
Duolink® proximity ligation assay (PLA®) (Sigma-Aldrich, DUO92101) was performed 
Immunofluorescence of post-mortem brains
To assess co-localization between GR aggregates and KIF5B in C9orf72 post-mortem brains we made use of the central nervous system (CNS) tissues previously collected in the UZ Leuven brain biobank in accordance with the ethics review board upon written informed consent. In this study, two C9orf72 expansion carriers (one ALS case and one ALS/FTD case) and two controls (ALS patients without the C9orf72 expansion) were used (Table S1 ).
Frozen frontal cortex slides of 7-8 µm thickness were washed with the BondTM Wash (102) .
Assessment of Drosophila viability and eye defects
Male GMR-Gal4 UAS-DPR (GR36 or PR36) flies were mated with females with altered Khc gene dosage or yw controls. Although GMR-Gal4 is predominantly expressed in the eye, its ability to cause lethality in combination with UAS-GR36 (20) indicates that it has some activity in other tissues (the eye is not required for survival to adulthood). Each type of cross was set up in triplicate, with at least two egg-lays (of three days each) analyzed per cross. Adult offspring were collected and aged to 4-6 days post-eclosion before analysis. For all crosses that produced a sufficient number of offspring (> 15 internal control animals that did not inherit the GMR-Gal4 UAS-DPR chromosome) we calculated the fraction of male flies of different genotypes that inherited the GMR-Gal4 UAS-DPR chromosome (male flies were used for all phenotypic analysis to control for any sex-specific phenotypic effects). These values were plotted as a percentage of the expected fraction for each genotype assuming no lethality.
For analysis of eye defects, a single eye per DPR-expressing male was scored using a qualitative scale of eye disruption (no, mild, moderate, severe, very severe, or total pigment loss; Table S6 ). Necrotic patches were not classed as pigmentation. See Fig. 6B and Fig.   S15A for example images for each category. All eye scoring was carried out blind of the genotypes to avoid unconscious bias. In control experiments, we confirmed that altering Khc gene dosage does not affect survival or eye morphology in the absence of expression of GR36 or PR36 (Table S6) .
Drosophila eye imaging
Example images of the different classes of eye phenotype were acquired using a Nikon 'Multiphot' macro photography set up, with a 6X Macro-Nikkor 35 mm lens and a Sony a6300 'mirrorless' 24 megapixel camera, followed by processing in Adobe Photoshop CS6.
Statistics
Statistical analyses and data plotting were performed using Prism 8 (GraphPad Table S3 for total numbers of neurites analyzed in each experiment). Statistical 
